Legend Biotech Plans USD 250M Secondary Offering to Fund CAR-T Therapy Development
China-based Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T cell...
CAR-T
GenScript ProBio Partners with ACT Therapeutics on CAR-T Cell Therapy Development
GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), announced a memorandum of understanding...
GenScript Biotech’s Legend Biotech Terminates LB1901 CAR-T Phase I Trial
Hong Kong-based GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ:...
Hrain Biotech and Novartis Receive Breakthrough Therapy Designations for CAR-T and Zolgensma
The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA –...
PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy
The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06,...
Legend Biotech Collaborates with Trinity College Dublin on CAR-T Therapies for Solid Tumors
China-based Legend Biotech Corporation (NASDAQ: LEGN) has formed a partnership with Trinity College Dublin and...
WuXi ATU Partners with Wugen to Accelerate NK Cell Therapy Development
WuXi ATU, the gene and cell therapy-focused CTDMO unit of WuXi Apptec (SHA: 603259, HKG:...
Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...
Genscript’s CAR-T Therapy JNJ-4528 Demonstrates 100% Effective Rate in Long-Term Myeloma Study
Genscript Biotech Corporation (HKG: 1548), a leading China-based Contract Development and Manufacturing Organization (CDMO), has...